Oncodetect™ Molecular Residual Disease test
Use
The Oncodetect Molecular Residual Disease (MRD) test is designed to detect subtle signs of residual cancer throughout a patient's care journey. It helps in identifying cancer recurrence and supports personalized treatment options by detecting tumor-specific DNA in the bloodstream, known as circulating tumor DNA (ctDNA). The test provides real-time measurement of the disease burden, which aids in making early detection and monitoring possible, thus empowering patients and providers to make informed treatment decisions. This test is particularly beneficial in determining post-surgical cancer presence, assessing recurrence likelihood, and evaluating response to treatment.
Special Instructions
The test is highly sensitive and tracks up to 200 variants specific to a patient's tumor, allowing for robust detection of ctDNA in the blood. It is supported by extensive experience in genomic oncology by Exact Sciences and is backed by clinical validation for use in colorectal cancer patients.
Limitations
The performance characteristics of the Oncodetect MRD test have been validated specifically for colorectal cancer patients with stage II-IV disease and may not apply to tumor types not included in its clinical validation. As the test has not been cleared or approved by the US Food and Drug Administration, its application in areas outside its validation scope should be carefully considered.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided